Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human phospholipase C zeta
- Development stage
- Preclinical
- Lead developer
- Weill Cornell Medicine
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Parenteral
01
Overview
Recombinant human phospholipase C zeta (rhPLCζ) is an investigational biologic therapeutic being developed for the treatment of oocyte activation failure (OAF) and male factor infertility. It is a recombinant version of the sperm-specific enzyme PLCζ1, which is responsible for triggering the intracellular calcium (Ca²⁺) oscillations necessary for oocyte activation and subsequent embryo development. In assisted reproduction, rhPLCζ is administered via microinjection during intracytoplasmic sperm injection (ICSI) to couples where the sperm lacks sufficient endogenous PLCζ or where previous fertilization attempts have failed. This approach aims to provide a more physiological stimulus than traditional chemical calcium ionophores. Clinical pilot studies, notably at Weill Cornell Medicine, have indicated that rhPLCζ can successfully rescue fertilization and lead to viable pregnancies in cases of sperm-related activation deficiencies.
- Other names
- recombinant human PLCζrecombinant human PLCZ1recombinant human phospholipase C zeta 1
02
Targets
PIP2 (Phosphatidylinositol 4,5-bisphosphate)
Beyond the preview
Go deeper on recombinant human phospholipase C zeta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human phospholipase C zeta.